Caisson Hogue, MD
Family Medicine · Summerville, SCNPI 1437230612
Payments from drug & device makers
Across 216 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$929
- Supernus Pharmaceuticals, Inc.$455
- Johnson & Johnson$172
- Pfizer$163
- Amgen$158
- Lilly USA, LLC$149
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,594100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $929 |
| Supernus Pharmaceuticals, Inc. | 19 | $455 |
| Johnson & Johnson | 12 | $172 |
| Pfizer | 10 | $163 |
| Amgen | 8 | $158 |
| Lilly USA, LLC | 9 | $149 |
| AstraZeneca | 8 | $120 |
| Boston Scientific | 7 | $115 |
| GSK | 6 | $114 |
| Jazz Pharmaceuticals Inc. | 5 | $110 |
| Novartis | 6 | $99 |
| Astellas Pharma US Inc | 5 | $96 |
| Novo Nordisk | 6 | $92 |
| Eisai Inc. | 5 | $70 |
| Teva Pharmaceuticals USA, Inc. | 4 | $54 |
| Sumitomo Pharma America, Inc. | 2 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $51 |
| Corium, LLC | 3 | $50 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| Abbott | 2 | $43 |
| Bausch Health US, LLC | 2 | $36 |
| Boehringer Ingelheim | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Medtronic | 2 | $33 |
| Stryker | 1 | $31 |
| Edwards Lifesciences | 1 | $31 |
| Endo Pharmaceuticals Inc. | 2 | $31 |
| Mayne Pharma Commercial LLC | 2 | $31 |
| Clarus Therapeutics Inc. | 2 | $29 |
| Merck | 2 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Bayer | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Acerus Pharmaceuticals Corporation | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Corcept Therapeutics | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
How this compares
$3,594 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 160 | $200,911 |
| EliquisApixaban | 121 | $140,282 |
| TrulicityDulaglutide | 100 | $118,438 |
| MounjaroTirzepatide | 92 | $116,640 |
| JanuviaSitagliptin Phosphate | 84 | $109,710 |
| FarxigaDapagliflozin Propanediol | 97 | $85,946 |
| JardianceEmpagliflozin | 48 | $55,518 |
| XareltoRivaroxaban | 22 | $31,263 |
| MyrbetriqMirabegron | 33 | $23,152 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $22,414 |
| LinzessLinaclotide | 20 | $18,008 |
| Repatha SureclickEvolocumab | 12 | $17,392 |
| OxycontinOxycodone Hcl | 22 | $13,324 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $10,917 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $9,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $149 | $235,078192 claims |
| Novo NordiskOzempic | $92 | $200,911160 claims |
| PfizerEliquis, Premarin | $163 | $143,970132 claims |
| MerckJanuvia | $25 | $109,71084 claims |
| AstraZenecaFarxiga | $120 | $85,94697 claims |
| Boehringer IngelheimJardiance | $35 | $55,51848 claims |
| Johnson & JohnsonXarelto | $172 | $31,26322 claims |
| Astellas Pharma US IncMyrbetriq | $96 | $23,15233 claims |
| GSKTrelegy Ellipta | $114 | $22,41421 claims |
| AbbVieLinzess, Synthroid | $929 | $21,60085 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Summerville
- Jennifer StolinSummerville$59K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.